Showing 651-660 of 1564 results for "".
Addressing COPD Exacerbations With Urgency
https://reachmd.com/programs/medical-industry-feature/addressing-copd-exacerbations-with-urgency/24225/Hear about the burden of chronic obstructive pulmonary disease (COPD) exacerbations and the role of early diagnosis and proactive care in addressing them.Illuminating AOX Serum from ZO Skin Health
https://modernaesthetics.com/topics/skincare/illuminating-aox-serum-from-zo-skin-health/35200/Nicotinamide for COVID-19 Recovery: Restoring Metabolic Balance
https://reachmd.com/programs/clinicians-roundtable/nicotinamide-for-covid-19-recovery-restoring-metabolic-balance/36410/Scientific Advancements Leading to New Options to Manage Aesthetic Concerns
https://modernaesthetics.com/topics/injectables/scientific-advancements-leading-to-new-options-to-manage-aesthetic-concerns/35185/Updates on some of the latest developments in minimially invasive aestheticsAre All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/Join us to learn about the emerging data with VMAT2 inhibitors for the treatment of tardive dyskinesia.Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/Join us to learn about the diagnosis of NPS associated with Alzheimer’s disease, as well as current and emerging agents for treatment.The Unmet Need in 1L HR+/HER2− Advanced Breast Cancer
https://reachmd.com/programs/medical-industry-feature/the-unmet-need-in-1l-hrher2-advanced-breast-cancer/36170/Over the past 50 years, endocrine therapies have improved patient outcomes in HR-positive, HER2-negative advanced breast cancer.1 However, after first-line treatment with an endocrine therapy plus a CDK4/6 inhibitor, the current standard of care, progression-free survival typically decreases with thAdvancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
https://reachmd.com/programs/cme/advancing-trop-2-targeted-adcs-in-hr-breast-cancer-navigating-today-and-shaping-tomorrow/29264/Learn about the role of TROP-2-targeted ADC therapy in the treatment of endocrine-resistant, hormone-positive, HER2-negative breast cancer.Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/Are you ready and willing to change your treatment approach for your patients with TNBC? Our experts break down the guidelines to get you on track.ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/Dr. Reshma Mahtani presents patient case challenges highlighting the use of antibody-drug conjugates in HER2-expressing metastatic breast cancer.